Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$23.1 million.

  • Outlook Therapeutics' Net Income towards Common Stockholders changed N/A to -$23.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$102.9 million, marking a year-over-year decrease of 16406.92%. This contributed to the annual value of -$62.4 million for FY2025, which is 1717.18% up from last year.
  • As of Q4 2025, Outlook Therapeutics' Net Income towards Common Stockholders stood at -$23.1 million.
  • Over the past 5 years, Outlook Therapeutics' Net Income towards Common Stockholders peaked at -$13.3 million during Q3 2025, and registered a low of -$46.4 million during Q1 2025.